title: Clinical aspects and therapeutic outcome in thyrotropin-secreting pituitary adenomas: a single center experience.
abstract: OBJECTIVE
  The management of pituitary adenomas secreting TSH has evolved considerably over the last decades.We report the clinical features, management, and outcome of a large monocentric series.
  
  
  METHODS
  A monocentric retrospective cohort of 26 patients admitted to our Department of Endocrinology between 1983 and 2007, followed for a period up to 204 months. The diagnosis of TSH-secreting adenoma was based on clinical and biochemical findings of central hyperthyroidism. Evaluation of basal and dynamic pituitary function, magnetic resonance imaging or computerized tomography scan were performed in all patients. Twenty-two patients, of whom 15 pre-treated by somatostatin analogs (SSA), underwent trans-sphenoidal surgery and were regularly re-evaluated.
  
  
  RESULTS
  The number of cases increased over the years. Age at diagnosis, micro- to macroadenoma ratio, and mean estimated latency between first symptoms and diagnosis did not appreciably change over time. Latency was significantly shorter in macroadenomas. Following surgery, 55% of patients obtained remission (success rate of 40 and 67% in macro- and microadenomas, respectively). SSA pre-treatment led to an apparent although not statistically- significant increase in success rate in micro- but not in macroadenomas.
  
  
  CONCLUSIONS
  In a monocentric group of 26 TSH-secreting adenomas the high ratio between micro- and macroadenomas remained stable over time with a significantly shorter diagnosis latency in macroadenomas. A more precocious recognition of the tumors and possibly the use of presurgical SSA allowed a high remission rate. A varied combination of neurosurgery, SSA, radiotherapy, and thyroid ablation led to the control of the disease in all the patients studied.
authors.affiliation: Department of Endocrinology and Metabolism, University of Pisa, Pisa 56124, Italy. emacchia@endoc.med.unipi.it
authors.forename: E
authors.initials: E
authors.lastname: Macchia
authors.forename: M
authors.initials: M
authors.lastname: Gasperi
authors.forename: M
authors.initials: M
authors.lastname: Lombardi
authors.forename: L
authors.initials: L
authors.lastname: Morselli
authors.forename: A
authors.initials: A
authors.lastname: Pinchera
authors.forename: G
authors.initials: G
authors.lastname: Acerbi
authors.forename: G
authors.initials: G
authors.lastname: Rossi
authors.forename: E
authors.initials: E
authors.lastname: Martino
mesh_terms: D000236:Adenoma / Q000175:diagnosis* / Q000188:drug therapy / Q000601:surgery; D000328:Adult; D000368:Aged; D015331:Cohort Studies; D005260:Female; D006801:Humans; D006980:Hyperthyroidism / Q000175:diagnosis; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D010901:Pituitary Function Tests; D010911:Pituitary Neoplasms / Q000175:diagnosis* / Q000188:drug therapy / Q000601:surgery; D012189:Retrospective Studies; D013004:Somatostatin / Q000031:analogs & derivatives / Q000627:therapeutic use; D013972:Thyrotropin / Q000378:metabolism*; D014057:Tomography, X-Ray Computed
chemical_list: D013004:Somatostatin; D013972:Thyrotropin